Moderna price target raised to $27 from $24 at BofA

BofA raised the firm’s price target on Moderna (MRNA) to $27 from $24 and keeps an Underperform rating on the shares. The company’s Q4 revenue came in slightly ahead of expectations but in-line with the roughly $1.9B FY25 revenue guidance given at the SF conference, the analyst tells investors in a research note. The firm added that it updated its model to reflect increased current cash position including initial draw from the credit facility, company guidance for 2026 and beyond, slightly increased ex-U.S./decreased U.S. COVID contributions, and updated probability of success for other oncology programs.